This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Look at Miglustat in Pompe patients after phase 3 PROPEL study results.
Ticker(s): FOLDWho's the expert?
Institution: Institute of Myology & Généthon (France)
- Pediatric neurologist, Senior Medical Manager Généthon, the AFM-Telethon laboratory dedicated to gene therapy & Deputy Director of the pediatric clinical trials platform of the Institute of Myology.
- Manages 5 patients with Pompe disease.
- Author or co-author of numerous publications in the fields of clinical and basic research.
Interview GoalDiscussing safety and efficacy of Miglustat in Pompe patients after phase 3 PROPEL study results.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
